Market closedNon-fractional

Xenon Pharmaceuticals/XENE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.

Ticker

XENE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Burnaby, Canada

Employees

255

XENE Metrics

BasicAdvanced
$3.3B
Market cap
-
P/E ratio
-$2.70
EPS
1.22
Beta
-
Dividend rate
$3.3B
1.22
31.823
31.518
1.025
1.174
-17.09%
-23.95%
3.69
3.69
-19.102
15.22%
45.08%

What the Analysts think about XENE

Analyst Ratings

Majority rating from 17 analysts.
Buy

XENE Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$48M
7.16%
Profit margin
0.00%
NaN%

XENE Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 6.66%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.72
-$0.73
-$0.64
-$0.62
-
Expected
-$0.70
-$0.77
-$0.76
-$0.66
-$0.70
Surprise
3.25%
-5.70%
-15.70%
-6.66%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Xenon Pharmaceuticals stock?

Xenon Pharmaceuticals (XENE) has a market cap of $3.3B as of July 23, 2024.

What is the P/E ratio for Xenon Pharmaceuticals stock?

The price to earnings (P/E) ratio for Xenon Pharmaceuticals (XENE) stock is 0 as of July 23, 2024.

Does Xenon Pharmaceuticals stock pay dividends?

No, Xenon Pharmaceuticals (XENE) stock does not pay dividends to its shareholders as of July 23, 2024.

When is the next Xenon Pharmaceuticals dividend payment date?

Xenon Pharmaceuticals (XENE) stock does not pay dividends to its shareholders.

What is the beta indicator for Xenon Pharmaceuticals?

Xenon Pharmaceuticals (XENE) has a beta rating of 1.22. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Xenon Pharmaceuticals stock

Buy or sell Xenon Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing